Literature DB >> 9671522

Trp82 and Tyr332 are involved in two quaternary ammonium binding domains of human butyrylcholinesterase as revealed by photoaffinity labeling with [3H]DDF.

F Nachon1, L Ehret-Sabatier, D Loew, C Colas, A van Dorsselaer, M Goeldner.   

Abstract

Purified butyrylcholinesterase (BuChE) was photolabeled by [3H]-p-N, N-dimethylamino benzene diazonium ([3H]DDF) to identify the quaternary ammonium binding sites on this protein [Ehret-Sabatier, L. , Schalk, I., Goeldner, M., and Hirth, C. (1992) Eur. J. Biochem. 203, 475-481]. The covalent photoincorporation occurs with a stoichiometry of one mole of probe per mole of inactivated site and could be fully prevented by several cholinergic inhibitors such as tacrine or tetramethylammonium. After complete deglycosylation of the enzyme using N-glycosidase F, the alkylated protein was trypsinolyzed and the digests were analyzed by HPLC coupled to ES-MS. A direct comparison of tryptic fragments from labeled and unlabeled BuChE allowed us to identify the tryptic peptide Tyr61-Lys103 as carrying the probe. Purification of the labeled peptides by anion-exchange chromatography gave a major radioactive peak which was further fractionated by reversed-phase HPLC leading to three, well-resolved, radioactive peaks. Microsequencing revealed that two of these peaks contained an overlapping sequence starting at Tyr61, while the third peak contained a sequence extending from Thr315. Radioactive signals could be unambiguously attributed to positions corresponding to residues Trp82 and Tyr332. This labeling study establishes the existence of two different binding domains for quaternary ammonium in BuChE and exemplifies additional cation/pi interactions in cholinergic proteins. This work strongly supports the existence of a peripheral anionic site in BuChE, implying residue Tyr332 as a key element.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671522     DOI: 10.1021/bi980536l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study.

Authors:  Terrone L Rosenberry; Xavier Brazzolotto; Ian R Macdonald; Marielle Wandhammer; Marie Trovaslet-Leroy; Sultan Darvesh; Florian Nachon
Journal:  Molecules       Date:  2017-11-29       Impact factor: 4.411

2.  Novel Tacrine-Scutellarin Hybrids as Multipotent Anti-Alzheimer's Agents: Design, Synthesis and Biological Evaluation.

Authors:  Katarina Spilovska; Jan Korabecny; Vendula Sepsova; Daniel Jun; Martina Hrabinova; Petr Jost; Lubica Muckova; Ondrej Soukup; Jana Janockova; Tomas Kucera; Rafael Dolezal; Eva Mezeiova; Daniel Kaping; Kamil Kuca
Journal:  Molecules       Date:  2017-06-16       Impact factor: 4.411

3.  The Preferable Binding Pose of Canonical Butyrylcholinesterase Substrates Is Unproductive for Echothiophate.

Authors:  A S Zlobin; A O Zalevsky; Yu A Mokrushina; O V Kartseva; A V Golovin; I V Smirnov
Journal:  Acta Naturae       Date:  2018 Oct-Dec       Impact factor: 1.845

4.  A hybrid of 1-deoxynojirimycin and benzotriazole induces preferential inhibition of butyrylcholinesterase (BuChE) over acetylcholinesterase (AChE).

Authors:  Tereza Cristina Santos Evangelista; Óscar López; Adrián Puerta; Miguel X Fernandes; Sabrina Baptista Ferreira; José M Padrón; José G Fernández-Bolaños; Magne O Sydnes; Emil Lindbäck
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

5.  Structure-based search for new inhibitors of cholinesterases.

Authors:  Marek Bajda; Anna Więckowska; Michalina Hebda; Natalia Guzior; Christoph A Sotriffer; Barbara Malawska
Journal:  Int J Mol Sci       Date:  2013-03-11       Impact factor: 5.923

6.  Probing the peripheral site of human butyrylcholinesterase.

Authors:  Ian R Macdonald; Earl Martin; Terrone L Rosenberry; Sultan Darvesh
Journal:  Biochemistry       Date:  2012-08-27       Impact factor: 3.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.